Evidence map›Paper›PMID 39945081›Full record

ArticleAdvanced biology2025

Considering the Risks and Costs of Solid Organ Xenotransplantation.

Catharine E Krebs, Janine McCarthy, Kristie Sullivan, James Craner, Brendan Parent, Ann Lam

Abstract read
In one paragraph

Article in Advanced biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Expanding the Donor Pool.Methodist DeBakey cardiovascular journal · 2025
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Catharine E KrebsPhysicians Committee for Responsible Medicine, 5100 Wisconsin Ave NW, Ste 400, Washington, DC, 20016, USA.ORCID https://orcid.org/0000-0002-6405-2665
Janine McCarthyPhysicians Committee for Responsible Medicine, 5100 Wisconsin Ave NW, Ste 400, Washington, DC, 20016, USA.ORCID https://orcid.org/0000-0001-5028-0483
Kristie SullivanPhysicians Committee for Responsible Medicine, 5100 Wisconsin Ave NW, Ste 400, Washington, DC, 20016, USA.ORCID https://orcid.org/0000-0002-5279-3271
James CranerIndependent Physician, 13505 Tremolite Dr, Reno, NV, 89511, USA.ORCID https://orcid.org/0000-0002-3675-8249
Brendan ParentNew York University Grossman School of Medicine, 227 E 30th Street, Ste 623, NY, NY, 10016, USA.ORCID https://orcid.org/0000-0003-3057-5684
Ann LamPhysicians Committee for Responsible Medicine, 5100 Wisconsin Ave NW, Ste 400, Washington, DC, 20016, USA.ORCID https://orcid.org/0009-0000-6286-1154

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The standard treatment for end-stage organ failure is transplantation, but demand for organs has always vastly outstripped supply. Discussions are ongoing about the feasibility of addressing the organ shortage through measures like increasing organ donations, improving post-transplant outcomes, and xenotransplantation. This paper examines the rationale, risks, and costs of xenotransplantation, such as xenozoonoses, creating a new form of industrialized animal farming, abandoning animal ethics principles, and the opportunity costs of investing finite research dollars in xenotransplantation instead of investing in more viable strategies. Alternative strategies that can ethically and effectively address the demand for heart, kidney, and other transplants are recommended: Improving disease prevention and management to reduce demand for transplant organs, improving transplantation methods, and systemic changes to donor policies and organ recovery methods to increase overall supply. Upon careful exploration of the full landscape of organ transplantation, it is considered whether these alternative strategies that do not impose the definite harms and significant risks of xenotransplantation are the most ethical and effective means to increase life-saving options and improve clinical outcomes for patients in organ failure.

Indexed as

Organ TransplantationTransplantation, HeterologousAnimalsHumansTissue and Organ Procurementchronic diseaseethicshealth policyorgan supplytransplantationxenotransplantation

Identifiers

PMID39945081
PMCPMC12001004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.